Slides
Page 1
Torrent Pharmaceuticals Limited Q1 FY2026-27 Earnings Call Presentation Highlights July 30, 2026
Page 2
Financial Performance Highlights Revenue ■4,921 Cr +55% YoY Growth EBITDA ■1,663 Cr Strong Profitability EBITDA Margin 33.8% Stable Margins Key Takeaways: Growth Driver: Exceptional top-line increase primarily propelled by the strategic integration of JB Chemicals. Operational Efficiency: Robust cost management maintained margins at a healthy 33.8%.
Page 3
Strategic Catalysts & Headwinds Core Growth Drivers JB Chemicals: Smooth early integration unlocking synergies. Domestic Strength: Robust volume growth across key chronic therapies. Market Expansion: Solid position scaling in high-margin segments. Key Challenges & Mitigations Product Recall: Encountered a temporary semaglutide batch recall campaign. Impact Control: Management confirmed the disruption is strictly short-term. Quality Guardrails: Rigorous internal compliance controls deployed.